Marseille-Kliniken AG

EANS-Adhoc: - Marseille-Kliniken Group disposing of its rehabilitation division - The transaction includes all rehabilitation clinics with a total of 1,269 beds - Sale generates a book gain in a lower double-digit EUR million range

-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Disposing of business division 21.04.2010 Berlin, 21 April 2010. Marseille-Kliniken Group (Prime Standard, ISIN DE 0007783003, MKA) has, as already announced some time ago, disposed of all rehabilitation clinic operations, thereby discontinuing the Group´s rehabilitation business. The closing of the sale depends on the approval of the annual general meeting of Karlsruhe Sanatorium AG as well as the lessor´s consent. This is to be completed by the beginning of May 2010. Capacities of 1,269 beds at seven locations in Germany are being sold. The transaction is impacting the investments in the rehabilitation clinics operated by Karlsruhe Sanatorium AG, a subsidiary of Marseille-Kliniken AG. It includes the Gotthard-Schettler-Klinik and REHA-Klinik Sigmund Weil, both located in Bad Schönborn, the specialist clinic for mental conditions Ortenau in Zell am Harmersbach, the clinic in Bad Herrenalb, the specialist clinic for psychosomatic conditions Schömberg as well as the psychosomatic clinic Kinzigtal in Gengenbach. Marseille-Kliniken AG also disposed of its investments in the rehabilitation companies Algos Fachklinik in Bad Klosterlausnitz, the sports and rehabilitation center Harz and Teufelsbad specialist clinic Blankenburg, both in Blankenburg/Harz. The clinic locations are each operated as limited companies (GmbH) and their shares were sold as part of this transaction. In return, Marseille-Kliniken Group will be recording a significant book gain amounting to a lower double-digit EUR million scope. Both parties agreed not to disclose the exact purchase amount involved. Marseille-Kliniken Group is making the sale to a joint venture held by funds which financial investor AUCTUS Capital Partners AG consults, and the existing management team around CEO Berthold Müller and Medical Director Professor Dr. Ulrich T. Egle and Professor Dr. Bernd E. Fromm. AUCTUS is Germany´s leading SME investment company and commands considerable expertise in the field of healthcare. The Rehabilitation division is profitable, it has not been part of the core business of Marseille-Kliniken Group in the recent past. The company has been reviewing a sale of the division for some time as a result. Generated inflows are to be invested in further developing the Care core business. End of ad hoc release end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: Marseille-Kliniken AG Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Hillermann Consulting Christian Hillermann Investor Relations for Marseille-Kliniken AG Poststraße 14/16 20354 Hamburg Germany Tel.: +49-(0)40 / 320 279-10 Fax: +49-(0)40 / 320 279-114 www.hillermann-consulting.de Marseille-Kliniken AG Dr. Ute Buchheim Friedrich-Ebert-Str. 65 33330 Gütersloh Germany Tel.: +49-(0)5241 / 90 39-35 Fax: +49-(0)5241 / 90 39-39 www.marseille-kliniken.com Branche: Pharmaceuticals ISIN: DE0007783003 WKN: 778300 Index: CDAX, Classic All Share, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Stuttgart / free trade Düsseldorf / free trade Hamburg / regulated dealing

Das könnte Sie auch interessieren: